Medical Health & Life Science Research News

Haemoglobinopathies market forecast to 2022 available in new report

Haemoglobinopathies market forecast to 2022 available in new report

Increasing incidences of hemoglobin disorders with strong product portfolio for sickle cell anemia such as HQK-1001 and Luspatercept, government’s awareness programs and advanced diagnostics and therapeutics will fuel the market growth.

- Advertisement -
- Membership expired -

Summary

The Global Hemoglobinopathie market is accounted for $4.6 billion in 2015 and is expected to reach $8.99 billion by 2022 growing at a CAGR of 10.0% from 2015 to 2022. 

Research & development and growth across developed and developing economies will provide opportunity for the market growth. Instrumentation cost and expertise required for LC MS/MS, molecular identification of the alpha and beta chain mutations are some of the factors that impede the market growth.

- Advertisement -
- Membership expired -

Hydroxyurea was one of the dominating segments followed by Thalassemia and is estimated to grow at lucrative growth rate. Blood tests and pre-implant genetic testing is anticipated to grow further during forecast period.

The market for blood transfusion was the largest with revenues in therapeutic segment. North America dominated the overall market.

Africa, Asia Pacific and the Mediterranean regions are projected to show profitable growth.

Request a Sample Report @ www.wiseguyreports.com/sample-requ…outlook-2016-2022

Some of the key players in global Hemoglobinopathie market are Gamida Cell,Alnylam Pharmaceuticals, Biogen Idec, Genetix Pharmaceuticals, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals, Sangamo BioSciences Inc, Cancer Therapeutics CRC Pty Ltd, Datar Genetics Limited, Optinova Ab, Anthera Pharmaceuticals and AcceleronPharma.

Disorders Covered: 
• Sickle Cell Disease 
• Haemoglobin variants diseases 
o Haemoglobin C disease 
o Haemoglobin S-C disease 
• Thalassemia 
Drugs Covered: 
• NiCord 
• ZFP Transcription Factors 
• ALN-TMP 
• Drug Targeting PRMT5 
• Drug Targeting Protein Arginine Methyltransferase 5 

Diagnosis Covered: 
• Genetic Testing 
• Blood Testing 
• Pre-implantation Genetic Diagnosis 
• Prenatal Genetic Testing 
• Haemoglobin Electrophoresis 

Therapies Covered: 
• Iron Chelation Therapy 
• Blood Transfusion 
• Hydroxyurea 
• Bone Marrow Transplant 

Regions Covered: 
• North America 
o US 
o Canada 
o Mexico 
• Europe 
o Germany 
o France 
o Italy 
o UK 
o Spain 
o Rest of Europe 
• Asia Pacific 
o Japan 
o China 
o India 
o Australia 
o New Zealand 
o Rest of Asia Pacific 
• Rest of the World 
o Middle East 
o Brazil 
o Argentina 
o South Africa 
o Egypt

What our report offers: 
- Market share assessments for the regional and country level segments 
- Market share analysis of the top industry players 
- Strategic recommendations for the new entrants 
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets 
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) 
- Strategic recommendations in key business segments based on the market estimations 
- Competitive landscaping mapping the key common trends 
- Company profiling with detailed strategies, financials, and recent developments 
- Supply chain trends mapping the latest technological advancements

……

At any Query @ www.wiseguyreports.com/enquiry/674…outlook-2016-2022

1 Executive Summary 
2 Preface 

 2.1 Abstract 
 2.2 Stake Holders 
 2.3 Research Scope 
 2.4 Research Methodology 
2.4.1 Data Mining 
2.4.2 Data Analysis 
2.4.3 Data Validation 
2.4.4 Research Approach 
 2.5 Research Sources 
2.5.1 Primary Research Sources 
2.5.2 Secondary Research Sources 
2.5.3 Assumptions 

……

11 Company Profiling 
11.1 Gamida Cell 
 11.2 Alnylam Pharmaceuticals 
 11.3 Biogen Idec 
 11.4 Genetix Pharmaceuticals 
 11.5 Global Blood Therapeutics Inc. 
 11.6 Pfizer Inc. 
 11.7 Mast Therapeutics 
 11.8 Emmaus Life Sciences, Inc. 
 11.9 Prolong Pharmaceuticals 
 11.10 Celgene Corporation 
 11.11 HemaQuest Pharmaceuticals 
 11.12 Sangamo BioSciences Inc 
 11.13 Cancer Therapeutics CRC Pty Ltd 
 11.14 Datar Genetics Limited 
 11.15 Optinova Ab 
 11.16 Anthera Pharmaceuticals 
 11.17 AcceleronPharma 

Enquire Now @ www.wiseguyreports.com/checkout?cu…;report_id=674249

News From

Wise Guy Reports - Market ResearchWise Guy Reports
Category: Market Research Publishers and RetailersCompany profile: Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs. Our Market Research Reports and Consulting Services  ...